Bullish
Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress
Roivant Sciences (ROIV) appears to be 19.5% undervalued following a US$2.25 billion settlement with Moderna, positive rheumatoid arthritis data for IM...